A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
NCT00585533
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
Erlotinib (Tarceva)
Sponsor
University of Utah